WO2000010991A1 - Inhibition et traitement du virus de l'hepatite b et de flavivirus par l'helioxanthine et ses analogues - Google Patents

Inhibition et traitement du virus de l'hepatite b et de flavivirus par l'helioxanthine et ses analogues Download PDF

Info

Publication number
WO2000010991A1
WO2000010991A1 PCT/US1999/019083 US9919083W WO0010991A1 WO 2000010991 A1 WO2000010991 A1 WO 2000010991A1 US 9919083 W US9919083 W US 9919083W WO 0010991 A1 WO0010991 A1 WO 0010991A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
dioxolane
hepatitis
compound
together form
Prior art date
Application number
PCT/US1999/019083
Other languages
English (en)
Inventor
Yung-Chi Cheng
Chen-Kung Chou
Lei Fu
Yueh-Hsiung Kuo
Sheau-Farn Yeh
Juliang Zhu
Yonglian Zhu
Original Assignee
Yale University
National Taiwan University
National Yang Ming University
Veterans General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, National Taiwan University, National Yang Ming University, Veterans General Hospital filed Critical Yale University
Priority to JP2000566264A priority Critical patent/JP2002523408A/ja
Priority to MXPA01001777A priority patent/MXPA01001777A/es
Priority to BR9913333-4A priority patent/BR9913333A/pt
Priority to CA002341540A priority patent/CA2341540A1/fr
Priority to AU55780/99A priority patent/AU5578099A/en
Priority to EP99942389A priority patent/EP1107961A4/fr
Publication of WO2000010991A1 publication Critical patent/WO2000010991A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Definitions

  • This invention relates to the anti-viral drugs such as Helioxanthin and its analogs compounds. These compounds may be used alone or in combination with other drugs for the treatment of the following: Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever Dengue Virus
  • Japanese Encephalitis West Nile virus
  • compounds according to the present invention can be used to prevent hepatoma secondary to virus infection as well as other infections or disease states which are secondary to the virus infection.
  • Hepatitis B virus infection is a major health problem worldwide.
  • HBV is a causative agent of both an acute and chronic form of hepatitis. More than 300 million people throughout the world are chronic carriers of HBV.
  • the human host is unaware of infection and HBV infection leads to acute hepatitis and liver damage, abdominal pain, jaundice and elevated blood levels of certain enzymes.
  • HBV contributes to the formation of hepatocellular carcinoma and is second only to tobacco as a cause of human cancer.
  • the mechanism by which HBV induces cancer is unknown, although it has been postulated that it may directly trigger tumor development or indirectly trigger tumor formation through chronic inflammation, cirrhosis and cell regeneration associated with the infection.
  • HBV belongs to the genus of hepadnavirus in the hepadnaviridae family.
  • the genome of HBV consists of circular, partially double-stranded DNA of about 3200 base pairs that code for seven viral proteins.
  • the polymerase gene completely overlaps the viral envelope genes PreSl, PreS2 and S and partially overlaps the X and core genes.
  • the envelope of HBV consists of three proteins and their glycosylated derivatives.
  • the three proteins, the small (S), middle (M) and large (L) are hepatitis B surface (HBs) proteins that contain the S gene sequence.
  • Other proteins such as the MHBs contain the PreS2 sequence.
  • the core gene contains the nucleocapsid protein (183-185 aa) and the hepatitis B core antigen.
  • the precore region, upstream of the core region, consists of 87 nucleotides that codes for 29 amino acids and is in phase with the core region.
  • the first 19 amino acids of the precore region act as a signal for membrane translocation and eventual secretion of the precore gene product, the Hbe antigen.
  • HBV DNA virus
  • Reverse transcriptase has poor proof-reading ability and this leads to a high rate of nucleotide misincorporation; calculations suggest that this error-prone replication leads to one point replacement, deletion or insertion per 1000 to 100,000 nucleotides copied.
  • anti-HBV nucleotide analogs such as 3TC, PCMEA, amd PCV have been used in clinical trials.
  • 3TC a period of treatment with 3TC or PCV; this recurrence is due to the emergence of viral resistance.
  • the 3TC-resistant HBV for example, becomes cross-resistant to other anti-HBV nucleotide analogs.
  • nucleoside analogs such as 2',3'-dideoxycytosine, which are liked through a 5' phosphate of the pentose group to selected lipids such as dioleoylphosphatidylcholine.
  • the lipophilic nature provides an advantage over the use of the nucleoside analog alone and makes it possible to incorporate them into the lamellar structure of liposomes. This form enables them to be taken up by liver cells which harbor the hepatitis B virus.
  • anti-HBV nucleotide analogs such as 3TC (L(-)SddC), PCMEA, amd PCV have been used in clinical trials.
  • 3TC L(-)SddC
  • PCMEA PCMEA
  • amd PCV have been used in clinical trials.
  • some HBV-infected patients often experience a recurrence of HBV after a period of treatment with 3TC or PCV; this recurrence is due to the emergence of viral resistance.
  • the 3TC-resistant HBV for example, becomes cross-resistant to other anti-HBV nucleotide analogs.
  • Flaviviruses belong to the genus Flavivirus of the family Togaviridae. According to virus taxonomy, about 50 viruses including Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis virus, West Nile virus and related flaviviruses. The viruses belonging to the genus Flavivirus are simply called flaviviruses.
  • HCV Hepatitis C virus
  • Yellow Fever virus Yellow Fever virus
  • Dengue Virus Dengue Virus
  • Japanese Encephalitis virus West Nile virus
  • Flaviviruses are simply called flaviviruses.
  • the flaviviruses are agents of infectious disease and predominate in East, Southeast and South Asia and Africa, although they may be found in other parts of the world as well.
  • Japanese encephalitis virus is the causative agent of Japanese encephalitis (JE).
  • the mortality rate from JE is rather high and the disease brings heavy sequelae.
  • Japan the disease has spread to other parts of Asia and is now found predominantly outside of Japan, primarily in South and Southeast Asia.
  • Dengue viruses are causative agents of dengue fever/dengue hemorrhagic fever. Infection with dengue viruses is a major public health problem in tropical countries, expecially in Southeast Asia and the Western Pacific, but dengue viruses may also be found in the Americas. As the dengue virus is transmitted to humans via the Aedes aegypti mosquito, it is not unexpected that the tropical and subtropical countries, in particular, those in Southeast Asia are highly endemic for dengue.
  • DHF dengue hemorrhagic fever
  • DSS shock syndrome
  • DHS/DSS is also found in a number of tropical or near tropical countries, including Cuba, Burma, Indonesia, India, Maldives, Sri Lanka and the South Pacific Islands. Dengue outbreaks are usually associated with a density of mosquito vectors, in particular, Aedes aegypti.
  • Dengue viruses can be divided into 4 serotpyes which are antigenically very similar to each other, but which differ enough to elicit only partial cross-protection after infection by one serotype. Such an infection by one serotype therefore, does not provide life-long immunity to the other serotypes.
  • Vaccine approaches to preventing dengue infections have been unsuccessful to date.
  • Acute viral hepatitis is a disease which many result in chronic liver damage. It is clinically diagnosed by a well-defined set of patient symptoms, including jaundice, hepatic tendrness and an increase in the serum levels of alanine aminotransferase and aspartate aminotransferase.
  • NANBH non-A, non-B hepatitis
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue Virus
  • Japanese Encephalitis West Nile virus and related flaviviruses and related conditions and/or disease states in patients.
  • FIGS 1A, IB and 1C represent the chemical structures of Helioxanthin and related analogs of the present invention.
  • Figures 2A and 2B represent the chemical scheme for the synthesis of compounds according to the present invention.
  • Figures 3 A and B and 4 A, B and C set forth biological data which is presented in the examples section which relates to HBV inhibition by certain compounds according to the present invention.
  • the present invention relates to the discovery that helioxanthin and its analogs, depicted in Figure 1A, B and C hereof, exhibit activity against Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue Virus
  • Japanese Encephalitis West Nile virus and related flaviviruses.
  • the activity the present compounds display against these viruses is unexpected, given the paucity of research on the activity of these agents in the prior art.
  • the present compounds also unexpectedly exhibit exceptional anti-HBV activity against 3TC (L(-)SddC) resistant HBV.
  • the present invention relates to compounds according to the structure:
  • A is H, OH, OR or forms a 1,3 dioxolane group with B such that A and B are O and are bridged together by a -CH 2 - (methylene) group;
  • B is OH, OR or forms a 1,3 dioxolane group with either A or C;
  • R is a C, to C 3 alkyl or a benzyl group or a C, to C 20 acyl group, preferably a C ] to C 7 acyl group;
  • D and E are the same or different and are selected from CH 3 , CH 2 OH, CH 2 OR, CHO, COOH,
  • R 1 is a C, to C 3 alkyl group
  • F and G are H or Br
  • I is H, OH, OR or Br and
  • J and K are the same or different and are selected from CH 3 , CH 2 OH, CH 2 OR, CHO, COOH,
  • the present invention also relates to a compound according to the structure:
  • the present invention relates to the discovery that helioxanthin and its analogs exhibit activity as agents to inhibit the growth, replication and /or elaboration of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses.
  • Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of flaviviruses. Certain of these agents are also useful for inhibiting the growth or replication of other viruses (for example, HSV by helioxanthin, among others) or for treating other viral infections and/or related disease states.
  • Other agents may be used as biological probes for testing purposes or as intennediates in the synthesis of related nucleoside compounds having pharmacological activity or for treating cancer and other disease states.
  • Compounds of the present invention find particular use in combating viral infections which afflict animals, and in particular, humans suffering from Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue virus, Japanese Encephalitis, West Nile virus and related flaviviruses and their complications, especially hepatoma which may be a secondary disease state precipitated by HBV or HCV infections.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue virus
  • Japanese Encephalitis West Nile virus and related flaviviruses and their complications, especially hepatoma which may be a secondary disease state precipitated by HBV or HCV infections.
  • Compounds according to the present invention offer great potential as therapeutic agents against certain disease states for which there presently are few, if any, real therapeutic options.
  • the compounds according to the present invention may be used alone or in combination with other anti-HBV or anti- flavivirus agents or other therapeutic treatments.
  • the compounds according to the present invention are based on the natural product helixoxanthin, which may be isolated from the plant of Taiwania cryptomerioides and related serial analogs. In a cell culture model, it was determined that helioxanthin selectively inhibited HBV replication and decreased the RNA level. Serial analogs were designed and synthesized and presented in the examples section of the present specification. The anti-viral activty, cytotoxicty and solubility of the compounds is summarized in Table 1. Interestingly, despite significant activity against HBV and Yellow Fever virus (YFV), the compounds exhibited relatively low toxicity. This is an unexpected result.
  • YFV Yellow Fever virus
  • the present invention also relates to methods for inhibiting the growth or replication of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue virus, Japanese Encephalitis, West Nile virus and related flaviviruses comprising exposing the virus to an inhibitory effective amount or concentration of at least one of the disclosed helioxanthin analogs.
  • This method may be used in comparison tests such as assays for determining the activities of related anti-viral compounds as well for determining the susceptibility of a patient's infection to one of the compounds according to the present invention.
  • the present compounds may be used to treat a number of viruses as explained, but the compounds are particularly suited for the treatment of HBV infections which are 3TC resistant.
  • the therapeutic aspect according to the present invention relates to methods for treating or preventing Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue virus, Japanese Encephalitis, West Nile virus and related flavivirus infections in patients, preferably, human patients, comprising administering anti-viral effective amounts of one or more of the compounds according to the present invention to inhibit the growth or replication of the virus in the animal or human patient being treated.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue virus
  • Japanese Encephalitis West Nile virus and related flavivirus infections
  • the present compositions are used to prevent or delay the onset of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flavivirus infections or related conditions or viral complications in a patient, espcially hepatoma, which may become a disease state secondary to a HBV or HCV infection.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue Virus
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile virus and related flavivirus infections or related conditions or viral complications in a patient, espcially hepatoma, which may become a disease state secondary to a HBV or HCV infection.
  • compositions based upon these novel chemical compounds comprise one or more of the above-described compounds in a therapeutically effective amount for treating a viral infection, in particular, a Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flavivirus infections.
  • a viral infection in particular, a Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flavivirus infections.
  • pharmaceutical compositions according to the present invention include one or more pharmaceutically acceptable additive, carrier or excipient.
  • the compounds according to the present invention in pharmaceutical dosage form, also may be used as prophylactic agents for inhibiting the growth or replication of a virus such as HBV or a flavivirus such as Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses.
  • a virus such as HBV or a flavivirus
  • HCV Hepatitis C virus
  • Yellow Fever virus Yellow Fever virus
  • Dengue Virus Dengue Virus
  • Japanese Encephalitis West Nile virus and related flaviviruses.
  • the pro-drug form for example, an acylated version of one of more of the analogs containing a hydroxyl side chain may be preferred.
  • the compounds according to the present invention may induce their inhibitory effect on the growth or replication of the virus by virtue of their ability to decrease or inhibt the synthesis of viral RNA, which leads to a decrease in viral RNA, the expression of the viral gene, a decrease in antigen expression and viral replication.
  • the compounds according to the present invention are produced by synthetic methods which are readily known to those of ordinary skill in the art and include various chemical synthetic methods which are presented in detail hereinbelow.
  • patient is used throughout the specification to describe an animal, preferably a human, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided.
  • treatment including prophylactic treatment
  • patient refers to that specific animal.
  • Hepatitis B Virus is used to describe the virus (serum hepatitis virus) which produces viral heptatis type B in humans. This is a viral disease with a long incubation period (about 50 to 160 days) in contrast to Hepatitis A virus (infectious hepatitis viurs) which has a short incubation period.
  • the virus is usually tramsmitted by injection of infected blood or blood derivatives or mrely by use of contaminated needles, lancets or other instruments.
  • the disease is similar to viral hepatitis type A; however, there is no cross-protective immunity.
  • Viral antigen (HBAg) is found in the serum after infection.
  • Hepatitis C Virus or (HCV) is used throughout the specification to describe the hepatitis virus which is the causative agent of non-A, non-B hepatitis.
  • HCV Hepatitis C Virus
  • the Disease in the acute stage is, in general, milder than hepatitis B, but a greater proportion of such infections become chronic.
  • flavivirus is used throughout the specification to describe viruses belonging to the genus Flavivirus of the family Togaviridae. According to virus taxonomy, about 50 viruses including Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis virus, West Nile virus and related flaviviruses are members of this genus. The viruses belonging to the genus Flavivirus are simply called flaviviruses. These viruses were formerly classified as group B arboviruses. The flaviviruses are agents of infectious disease and predominate in East, Southeast and South Asia and Africa, although they may be found in other parts of the world as well.
  • HCV Hepatitis C virus
  • Yellow Fever virus Yellow Fever virus
  • Dengue Virus Dengue Virus
  • Japanese Encephalitis virus West Nile virus
  • West Nile virus and related flaviviruses are members of this genus.
  • the viruses belonging to the genus Flavivirus are simply called flaviviruses. These viruses were formerly classified
  • Yellow Fever virus is used to describe the flavivirus which is the causative agent of yellow fever.
  • Yellow fever is a tropical mosquito-borne viral heptatitis, due to Yellow Fever virus (YFV), with an urban form transmitted by Aedes aegypti, and a rural, jungle or sylvatic form from tree-dwelling mammals by various mosquitos of the Haemagogus species complex.
  • Yellow fever is characterized clinically by fever, slow pulse, albuminuria, jaundice, congesion of the face and hemorrhages, especially hematemesis ("black vomit"). It is fatal in about 5-10% of the cases.
  • JEV Japanese encephalitis virus
  • JE Japanese encephalitis virus
  • JE is an epidemic encephalitis or encephalomyelitis of Japan, Russia (Siberia) and other partis of Asia.
  • the mortality rate from JE is rather high and the disease brings heavy sequelae.
  • the disease has spread to other parts of Asia and is now found predominantly outside of Japan, primarily in South and Southeast Asia.
  • Dengue virus is used throughout the specification to descibe the flavivirus which is the causative agent(s) of dengue fever/dengue hemorrhagic fever.
  • Dengue is a disease of tropical and subtropical regions occurring epidemically and caused by Dengue virus, one of a group of arboviruses which causes the hemorrhagic fever syndrome.
  • grade I fever and constitutional symptoms
  • grade II grade I plus spontaneous bleeding (of skin, gums or gastrointestinal tract)
  • grade III grade II plus agitation and circulatory failure
  • grade IV profound shock.
  • the disease is transmitted by a mosquito of the genus Aedes (generally A. aegyptil, but frequently, A. albopictus).
  • Dengue also called Aden, bouquet, breakbone, dandy, date, dengue (hemorrhagic) or polka , solar fever, stiffneck fever, scarlatina rheumatica or exanthesis arthorosia.
  • "Hemorrhagic dengue” is a more pathogenic epidemic form of dengue which has erupted in a number of epidemic outbreaks in the Pacific region in recent years.
  • 'West Nile virus is used to describe the flavivirus which is the causative agent of West Nile fever, a disease characterized by headache, fever, masculopapular rash, myalgia, lymphadenopathy and leukopenia.
  • the virus is spread by Culex mosquitoes from a reservoir in birds.
  • pharmaceutically acceptable salt is used throughout the specification to describe a salt form of helioxanthin or one or more of its serial analogs described herein which are presented to increase the solubility of the compound in the gastic juices of the patient's gastrointestinal tract in order to promote dissolution and the bioavailability of the compounds.
  • Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, among numerous other acids well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralization salts of carboxylic acids.
  • pharmaceutically acceptable derivative is used throughout the specification to describe any pharmaceutically acceptable prodrug form (such as an ester or other prodrug group) which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.
  • acyl is used throughout the specification to describe a group at the 5' position of the nucleoside analog (i.e., at the free hydroxyl position in the dioxolanyl moiety) which contains a C, to C 20 linear, branched, aromatic or cyclic alkyl (e.g., cyclopentyl, cyclohexyl) chain.
  • Acyl groups according to the present invention are
  • R is a C, to C 20 linear, branched, aromatic or cyclic alkyl chain, alkoxyalkyl, aryloxyalkyl, such as phenoxymethyl, aryl, alkoxy, among others.
  • Preferred acyl groups are those where R is C, to C 7 .
  • Acyl groups according to the present invention also include, for example, those acyl groups derived from benzoic acid and related acids, 3-chlorobenzoic acid, succinic, capric and caproic, lauric, myristic, palmitic, stearic and oleic, among numerous others including mesylate groups.
  • inhibitory effective concentration or “inhibitory effective amount” is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which substantially or significantly inhibit the growth or replication of susceptible viruses, especially including Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue Virus
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile virus and related flaviviruses.
  • terapéutica effective amount or “therapeutically effective amount” is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which are therapeutically effective in treating Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flavivirus infections in patients.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue Virus
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile virus and related flavivirus infections in patients.
  • preventing effective amount is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which are prophylactically effective in preventing or delaying the onset of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flavivirus infections or related conditions (especially heptatitis- associated hepatoma) in humans.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue Virus
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile virus and related flavivirus infections or related conditions especially heptatitis- associated hepatoma
  • an effective amount shall mean an amount or concentration of a compound according to the present mvention which is effective within the context of its administration.
  • Pure compounds according to the present invention are those which preferably comprise at least 95% by weight of the desired compound, more preferably at least about 97-98% by weight of the desired compound and even more preferably about 99+%o by weight of the desired compound.
  • Pure compounds according to the present invention in particular, helioxanthin, are distinguished from compounds which may be found in their natural state, for example, as the metabolic products of biosynthesis by living organisms. Pure compounds include those natural products which have been isolated from a plant or other organism and are in a form which is used to deliver active compound for the treatment of a virus.
  • antionmerically enriched is used throughout the specification to describe a compound which includes at least about 95%, preferably at least about 96%>, more preferably at least about 97%, even more preferably, at least about 98%>, and even more preferably at least about 99% or more of a single enantiomer of the described compound. Where the enatiomeric enrichment of a compound is unstated, it is presumed (unless the chemistry dictates otherwise) that the compound is a racemic mixture.
  • the present invention therefore relates to a group of compounds according to the structure:
  • A is H, OH, OR or forms a 1,3 dioxolane group with B such that A and B are O and are bridged together by a -CH 2 - (methylene) group;
  • B is OH, OR or forms a 1,3 dioxolane group with either A or C;
  • R is a C, to C 3 alkyl group, a benzyl group or a C, to C 20 acyl group, preferably a C, to C 7 acyl group;
  • D and E are the same or different and are selected from CH 3 , CH 2 OH, CH 2 OR, CHO, COOH,
  • R 1 is a C, to C 3 alkyl group
  • F and G are H or Br
  • I is H, OH, OR or Br and
  • J and K are the same or different and are selected from CH 3 , CH 2 OH, CH 2 OR, CHO, COOH,
  • the present invention also relates to a compound according to the structure:
  • the present compounds exhibit unexpectedly high activity against Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses.
  • HBV Hepatitis B virus
  • HCV Hepatitis C virus
  • Yellow Fever virus Dengue Virus
  • Japanese Encephalitis West Nile virus and related flaviviruses.
  • the compounds according to the present invention show potent inhibition of the replication of the virus (viral growth) in combination with very low toxicity to the host cells (i.e., animal or human tissue).
  • HBV Hepatitis B virus
  • HCV Hepatitis C vims
  • Yellow Fever virus Dengue Virus
  • Japanese Encephalitis West Nile virus and related flaviviruses.
  • Certain of these agents are also useful for inhibiting the growth or replication of other viruses (for example, HSV) or for treating other viral infections and/or related disease states.
  • Other agents may be used as biological probes for testing purposes or as intermediates in the synthesis of related nucleoside compounds having pharmacological activity or for treating cancer and other disease states.
  • Compounds of the present invention find particular use in combating viral infections which afflict animals, and in particular, humans suffering from Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivirus infections and their complications.
  • Compounds according to the present invention offer great potential as therapeutic agents against a number of disease states for which there presently are few real therapeutic options.
  • the present invention find particular use to treat HBV infections which are 3TC (lamivudine) resistant.
  • the compounds according to the present invention may be used alone or in combination with agents or other therapeutic treatments.
  • the present invention also relates to methods for inhibiting the growth or replication of Hepatitis B virus (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivirus comprising exposing the vims to an inhibitory effective amount or concentration of at least one of the disclosed nucleoside analogs.
  • This method may be used in comparison tests such as assays for determining the activities of related anti-viral compounds as well for determining the susceptibility of a patient's viral infection to one of the compounds according to the present invention.
  • the present compounds are preferably used to treat or prevent 3TC-resistant HBV infections and HCV infections in humans.
  • the therapeutic aspect according to the present invention relates to methods for treating or preventing Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivirus infections in patients, preferably, human patients, comprising administering anti-viral effective amounts of one or more of the compounds according to the present invention to inhibit the growth or replication of the vims in the animal or human patient being treated.
  • HBV Hepatitis B vims
  • HCV Hepatitis C vims
  • Yellow Fever vims Dengue Vims
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile vims West Nile vims and related flavivirus infections
  • the present compositions are used to prevent or delay the onset of Hepatitis B virus (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Virus, Japanese Encephalitis, West Nile virus and related flavivirus infections or related conditions or viral complications in a patient, especially including hepatoma in those patients who have been infected with HBV or HCV.
  • HBV Hepatitis B virus
  • HCV Hepatitis C vims
  • Yellow Fever vims Dengue Virus
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile virus and related flavivirus infections or related conditions or viral complications in a patient, especially including hepatoma in those patients who have been infected with HBV or HCV.
  • compositions based upon these novel chemical compounds comprise one or more of the above-described compounds in a therapeutically effective amount for treating a viral, generally, a Hepatitis B virus (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Virus, Japanese Encephalitis, West Nile vims and related flavivirus infection, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.
  • a viral generally, a Hepatitis B virus (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Virus, Japanese Encephalitis, West Nile vims and related flavivirus infection, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.
  • HBV Hepatitis B virus
  • HCV Hepatitis C vims
  • Yellow Fever vims Yellow Fever vims
  • Dengue Virus Dengue Virus
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile vims
  • the compounds according to the present invention in pharmaceutical dosage form, also may be used as prophylactic agents for inhibiting the growth or replication of Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivims. These may be particularly appropriate as anti-viral agents.
  • the pro-dmg form for example, an acylated form of the compound to promote dissolution, absorptivity or bioavailability may be preferred.
  • HBV Hepatitis B vims
  • HCV Hepatitis C vims
  • Yellow Fever vims Dengue Vims
  • Japanese Encephalitis West Nile vims and related flaviviruses.
  • the present compounds also exhibit unexpected activity against 3TC resistant HBV.
  • helioxanthin in cell cultures has shown a stronger inhibition of viral replication of strains of HBV that have become resistant to 3TC. Furthermore, the helioxanthin compounds have a unique mechanism of anti-viral action. It is believed that helioxanthin No. 145, is the only compound that could simultaneously decrease the RNA level of HBV and its antigen expression as well as inhibit HBV replication in cell culture. In contrast to other nucleotide analogs which only inhibit HBV during viral DNA synthesis, helioxanthin compounds according to the present invention inhibit the virus at an early stage of the viral cycle in which HBV replicates via reverse transcription of a 3.5 kb pregenomic RNA as well as viral gene expression in vims DNA expression cells..
  • the Helioxanthin compounds could preferentially decrease viral RNA in cells; therefore, viral gene expression and replication could also decrease.
  • the unique anti-viral action of the has never been found in drugs that have been used or evaluated in clinical trials.
  • the critical site of the stmcture in helioxanthin that is responsible for anti-viral activity has recently been elucidated.
  • helioxanthin compounds according to the present invention can be used alone or in combination with other drags for the treatment of HBV infection, or an infection of flavivims including Yellow fever vims, Hepatitis C vims, Danque fever vims, Japanese Encephalitis vims, West Nile vims as well as the prevention of diseases associated with these vimses including hepatoma.
  • the present compounds are preferably used in pharmaceutical dosage form.
  • the compound according to the present invention is formulated preferably in admixture with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier In general, it is preferable to administer the pharmaceutical composition in orally-administrable form, but certain formulations may be administered via a parenteral, intravenous, intramuscular, transdermal, buccal, subcutaneous, suppository or other route. Intravenous and intramuscular formulations are preferably administered in sterile saline.
  • one of ordinary skill in the art may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.
  • the modification of the present compounds to render them more soluble in water or other vehicle may be easily accomplished by minor modifications (salt formulation, esterification, etc.) which are well within the ordinary skill in the art. It is also well within the routineer's skill to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.
  • the pro-dmg form of the compounds especially including acylated (acetylated or other) and ether derivatives and various pharmaceutically acceptable salt forms of the present compounds, are preferred.
  • acylated (acetylated or other) and ether derivatives and various pharmaceutically acceptable salt forms of the present compounds are preferred.
  • One of ordinary skill in the art will recognize how to readily modify the present compounds to pro-dmg forms to facilitate delivery of active compounds to a targeted site within the host organism or patient.
  • the routineer also will take advantage of favorable pharmacokinetic parameters of the pro-dmg forms, where applicable, in delivering the present compounds to a targeted site within the host organism or patient to maximize the intended effect of the compound.
  • the amount of compound included within therapeutically active formulations according to the present invention is an effective amount for treating the infection or condition, in preferred embodiments, a Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever virus, Dengue Virus, Japanese Encephalitis, West Nile virus and related flavivims infection.
  • a therapeutically effective amount of the present compound in pharmaceutical dosage form usually ranges from about 0.1 mg/kg to about 100 mg/kg or more, more preferably, slightly less than about 1 mg./kg. to about 50 mg./kg. of the patient or considerably more, depending upon the compound used, the condition or infection treated and the route of administration.
  • the active compound is preferably administered in amounts ranging from about 0.5 mg/kg to about 25 mg/kg of the patient, depending upon the pharmacokinetics of the agent in the patient.
  • This dosage range generally produces effective blood level concentrations of active compound which may range from about 0.05 to about 100 micrograms/cc of blood in the patient.
  • a prophylactically or preventive effective amount of the compositions according to the present invention falls within the same concentration range as set forth above for therapeutically effective amount and is usually the same as a therapeutically effective amount.
  • the concentration of active compound in the dmg composition will depend on absorption, distribution, inactivation, and excretion rates of the dmg as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
  • the active compounds or their pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as other antivirals, or depending upon the desired target or therapy, antibiotics, antifungals, antinflammatories.
  • Administration of the active compound may range from continuous (intravenous drip) to several oral administrations per day (for example, Q.I.D.) and may include oral, topical, parenteral, intramuscular, intravenous, sub-cutaneous, transdermal (which may include a penetration enhancement agent), buccal and suppository administration, among other routes of administration.
  • Enteric coated oral tablets may also be used to enhance bioavailability of the compounds from an oral route of administration.
  • the most effective dosage form will depend upon the pharmacokinetics of the particular agent chosen as well as the severity of disease in the patient. Oral dosage forms are particularly preferred, because of ease of admnistration and prospective favorable patient compliance.
  • a therapeutically effective amount of one or more of the compounds according to the present invention is preferably intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques to produce a dose.
  • a carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral.
  • any of the usual pharmaceutical media may be used.
  • suitable carriers and additives including water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents and the like may be used.
  • suitable carriers and additives including starches, sugar carriers, such as dextrose, mannitol, lactose and related carriers, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be used.
  • the tablets or capsules may be enteric-coated or sustained release by standard techniques. The use of these dosage forms may significantly the bioavailability of the compounds in the patient.
  • the carrier will usually comprise sterile water or aqueous sodium chloride solution, though other ingredients, including those which aid dispersion, also may be included.
  • sterile water is to be used and maintained as sterile, the compositions and carriers must also be sterilized.
  • injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • Liposomal suspensions may also be prepared by conventional methods to produce pharmaceutically acceptable carriers. This may be appropriate for the delivery of free nucleosides, acyl nucleosides or phosphate ester prod- drug forms of the nucleoside compounds according to the present invention.
  • the compounds and compositions are used to treat, prevent or delay the onset of viral infections of mammals and in particular, Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivims infections in humans.
  • HBV Hepatitis B vims
  • HCV Hepatitis C vims
  • Yellow Fever vims Dengue Vims
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile vims and related flavivims infections in humans.
  • the compounds are used to treat HBV, and HCV infections, especially 3TC resistant HBV infections in humans.
  • the compositions will be administered in oral dosage form in amounts ranging from about 250 micrograms up to about 500 mg or more at least once a day, preferably, up to four times a day.
  • the present compounds are preferably administered orally, but may be administered parenterally, topically or in suppository form.
  • the compounds according to the present invention because of their low toxicity to host cells, may advantageously be employed prophylactically to prevent Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivims infection infections or to prevent the occurrence of clinical symptoms associated with the viral infection, especially hepatoma in those patients with HBV or HCV viral infections.
  • HBV Hepatitis B vims
  • HCV Hepatitis C vims
  • Yellow Fever vims Dengue Vims
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile vims and related flavivims infection infections
  • the present invention also encompasses methods for the prophylactic treatment of viral infections, and in particular Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivims infection infections.
  • the present compositions are used to prevent or delay the onset of an Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Virus, Japanese Encephalitis, West Nile vims and related flavivims infection or a related disease such as hepatoma in patients, among others.
  • This prophylactic method comprises administering to a patient in need of such treatment or who is at risk for the devolopment of a Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivims infection or related symptoms or diseases an amount of a compound according to the present invention effective for alleviating, preventing or delaying the onset of the the viral infection.
  • HBV Hepatitis B vims
  • HCV Hepatitis C vims
  • Yellow Fever vims Dengue Vims
  • Japanese Encephalitis Japanese Encephalitis
  • West Nile vims and related flavivims infection or related symptoms or diseases an amount of a compound according to the present invention effective for alleviating, preventing or delaying the onset of the the viral infection.
  • the antiviral compound utilized should be as low in toxicity and preferably non-toxic to the patient.
  • the compound which is used should be maximally effective against the vims and should exhibit a minimum of toxicity to the patient.
  • these may be administered within the same dosage range for therapeutic treatment (i.e., about 250 micrograms up to about 500 mg. or more from one to four times per day for an oral dosage form) as a prophylactic agent to prevent the proliferation of a vims infection, or to prolong the onset of a vims infection which manifests itself in clinical symptoms.
  • compounds according to the present invention may be administered alone or in combination with other agents, including other compounds of the present invention.
  • Certain compounds according to the present invention may be effective for enhancing the biological activity of certain agents according to the present invention by reducing the metabolism, catabolism or inactivation of other compounds and as such, are co-administered for this intended effect.
  • an inhibitory effective amount of at least one compound according to the present invention in pharmaceutical dosage form is administered to a patient suffering from such an infection to treat the infection and alleviate the symptoms of such infection.
  • compounds according to the present invention may be administered alone or in combination with other agents, especially including other compounds of the present invention or compounds which are otherwise disclosed as being useful for the treatment of Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivims infection, such as those relevant compounds and compositions which are disclosed in the following United States patents, which are incorporated by reference herein: U.S No.
  • the compounds disclosed in the above- referenced patents may be used in combination with the present compounds for their additive activity or treatment profile against Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivims infections and, in certain instances, for their synergistic effects in combination with compounds of the present invention.
  • Preferred secondary or additional compounds for use with the present compounds are those which do not inhibit Hepatitis B vims (HBV), Hepatitis C vims (HCV), Yellow Fever vims, Dengue Vims, Japanese Encephalitis, West Nile vims and related flavivims infection by the same mechanism as those of the present invention.
  • the compounds according to the present invention are produced by synthetic methods which are readily known to those of ordinary skill in the art and include various chemical synthetic methods which are presented in detail hereinbelow.
  • Compound 5 was reduced using lithium aluminium hydride and aluminum chloride (Arylnapthalene Lignans: synthesis of Helioxanthins. Holmes, T.L. and Stevenson, R. J.Chem. Soc. (C), 1971, 2091) in THF for three days to give 3-methyl-5,6-methylenedioxy-4- (3', 4'-methylenedioxyphenyl)-2-hydroxymethylnapthalene (12).
  • Oxidation of compound 12 using silver carbonate-cellite reagent (Arylnapthalene Lignans: synthesis of Helioxanthins. Holmes, T.L. and Stevenson, R. J.Chem. Soc. (C), (1971), 2091 and Synthesis of Helioxanthin.
  • the silver carbonate-cellite reagent (5.26 g) was added to a solution of compound 12 (270 mg, 0.80 mmol) in benzene (400 ml). The solvent was distilled off until the vapour temperature reached 80°C. The mixture was heated under reflux for 2 h. The reaction mixture was filtered and cooled.
  • the compound was synthesized from 10 (20 mg, 0.057 mmol) by the methodology as described for the synthesis of 18: yield 16 mg (72%) as white crystals; mp (213-215°C; 'HNMR (d 6 -DMSO) ⁇ 7.73 (s, IH, 1-H), 7.45 (d, IH, 7-H), 7.19 (d, IH, 8-H), 7.08 and 6.79 (2s, 3H 2', 3', and 6'-H), 6.06 (d, 2H, 5,6-methylenedioxy group), 5.79 (d, 2H, 3',4'- methylenedioxy group), 4.50 (m, 2H, 3-CH 2 ), 1.22 (s, IH, OH, D 2 O exchangeable).
  • the biological activity of the present compounds was assessed as described by Doong, S-L, et al, Proc. Natl. Acad. Sci. U.S.A 88, 8495-8499 (1991).
  • the human hepatoma cell line carrying HBV (cell line designated 2.2.15) provided by Dr. G. Aces was used in the study.
  • the drug was left in the culture medium for a period of 3 days after which period the medium was aspirated and fresh medium containing the same concentration(s) of the dmg was added. At the end of the subsequent 3 day period, the culture medium was harvested. The culture medium was processed for obtaining the virions by the polyethylene glycol precipitation method (Doong, et al., supra). Viral DNA thus recovered from the secreted particles was subjected to Southern analysis. Inhibition of the viral replication was determined by the comparison of the viral DNA from dmg-treated versus control cultures not treated with the dmg.
  • RNA levels were determed using Northern analysis with cellular albumin RNA being measured as a load control to standardize the quality of the HBV RNA measurement ( Figure 3B).
  • the T-lymphoblastoic cell line (CEM) and the HEP-G2 cell line (parent cell line from which 2.2.15 cell line is produced) were used.
  • Cells were subjected to varying concentrations of the dmg(s) and cell numbers were determined 3 days post treatment by the method described by Chen, C-H and Cheng, Y-C, J. Biol. Chem.. 264, 11934 (1989). Concentrations of the dmg which would result in inhibition of cell growth were determined from the plot generated by representing cell numbers corresponding to the individual dmg concentrations. Results of the cytotoxicity study are set forth in Figure 3A hereof.
  • Figs. 3 A and 3B respectively, compound no. 145 (helioxanthin) selectively inhibited HBV replication, antigen expression and decreased the RNA and DNA level.
  • Serial analogs have been designed and synthesized.
  • Figures 1 A, B and C and show such compounds.
  • the anti-viral activity, cytotoxicity and solubility of a number of these agents are summarized in Table 1, below.
  • Table 2 further describes the anti-HBV activity of several of these compounds by measurement of the suppression of HBV antigen expression in HepA2 and Hep3B cell lines.
  • the cell line HepG2 was transfected with plasmids which contained a double mutation which conferred resistance to 3TC following the procedure of Fu and Cheng, Biochem. Pharm., 55, 1567-1572 (1998) and Biochem. Pharm.. 57, 1351-1359 (1999).
  • HBV genome constructs were introduced into a retro-viral vector according to that same procedure. These vectors included wild-type (WT) with no mutation for 3TC resistance and L526MM550V (DM) for double mutation evidencing strong 3TC resistance.
  • Each of these retro-viral vectors was transfected into HepG2 cells. Promising cell cultures which secreted HBV antigen (HbsAg and HbeAg) were selected. Among those selected cells, some could secrete HBV virion. The colonies WT10 and DM2 were selected as models to do further characterization studies. A dose response relationship developed for these cell lines indicated that the HBV DNA production of WT10 was sensitive to 3TC (L(-)SddC) and that of DM2 was resistant to 3TC.
  • transient transfected HEPG2 cells were treated with varying concentrations of helioxanthin no. 145 to determine whether helioxanthin had any impact on 3TC resistant HBV.
  • the transient transfected HepG2 cells (WT and DM2 described above) were treated with an appropriate concentration of helioxanthin when the original calcium phosphate precipitated medium was replaced. Every 3 days, a half volume of fresh medium containing helioxanthin at a certain concentration was added (see Figures 4A, 4B and 4C). After 9 days, the cultures were harvested and the HBV progeny were tested for DNA content (Southern analysis).
  • HBV antigens HBV antigen and HBVs antigen
  • helioxanthin had essentially the same effect on 3TC resistant HBV (DM2) as on 3TC sensitive HBV.
  • DM2 3TC resistant HBV
  • helioxanthin 145 evidences excellent anti-HBV activity even in 3TC (L(-)SddC) resistant HBV and can be used therapeutically for treatment of 3TC resistant HBV and in combination therapy with 3TC for the treatment of HBV infections.
  • Baby Hamster Kidney (BHK) cells were seeded onto 24 well dishes at 5 X 10 5 cells per well in RPMI 1640 + 5%o FBS cell medium in 0.1% methyl cellulose (viscosity 15cps). The cells were incubated overnight in 5% CO 2 at 37°C overnight. The incubated cells were infected with yellow fever at 30 PFU in the presence or absence of drags (see Table I, below). The infected cells were incubated at 37°C in 5% CO 2 for 30 minutes and overlayed with drags in RPMI + 2%> FBS + 1% methyl cellulose (viscosity 4,000cps).
  • the cells in this state were incubated for 6 days at 37°C in 5% CO 2 , after which time the cells in each well were stained with 0.8%o Crystel Violet.
  • the ED 50 value was determined by plotting the percent of control (number of plaques in untreated cells) versus the number of plaques in cells at the tested drag concentrations. Those values appear in Table I, below.
  • No. 145 and its analog 157 also demonstrated activity against the Yellow fever virus.
  • No. 145 alone showed anti-HSV activity in the HSV-I , HSV- II and HSV TK minus strain.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des médicaments antiviraux tels que l'hélioxanthine et ses analogues. Les composés selon l'invention peuvent être utilisés seuls ou combinés avec d'autres médicaments pour combattre les virus de l'hépatite B (HBV), de l'hépatite C (HCV), de la fièvre jaune, de la dengue, de l'encephalite japonaise, West Nile et autres flavivirus. De plus, ces composés peuvent être utilisés pour prévenir un carcinome hépatocellulaire secondaire à une infection virale ainsi que d'autres infections ou états pathologiques faisant suite à une infection virale.
PCT/US1999/019083 1998-08-25 1999-08-23 Inhibition et traitement du virus de l'hepatite b et de flavivirus par l'helioxanthine et ses analogues WO2000010991A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2000566264A JP2002523408A (ja) 1998-08-25 1999-08-23 ヘリオキサンチンおよびその類似体によるｂ型肝炎ウイルスおよびフラビウイルスの阻害および治療
MXPA01001777A MXPA01001777A (es) 1998-08-25 1999-08-23 Inhibidores y tratamiento del virus de la hepatitis b y el flavivirus por la helioxantina y sus analogos.
BR9913333-4A BR9913333A (pt) 1998-08-25 1999-08-23 Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
CA002341540A CA2341540A1 (fr) 1998-08-25 1999-08-23 Inhibition et traitement du virus de l'hepatite b et de flavivirus par l'helioxanthine et ses analogues
AU55780/99A AU5578099A (en) 1998-08-25 1999-08-23 Inhibition and treatment of hepatitis b virus and flavivirus by helioxanthin andits analogs
EP99942389A EP1107961A4 (fr) 1998-08-25 1999-08-23 Inhibition et traitement du virus de l'hepatite b et de flavivirus par l'helioxanthine et ses analogues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9802598P 1998-08-25 1998-08-25
US60/098,025 1998-08-25

Publications (1)

Publication Number Publication Date
WO2000010991A1 true WO2000010991A1 (fr) 2000-03-02

Family

ID=22266367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/019083 WO2000010991A1 (fr) 1998-08-25 1999-08-23 Inhibition et traitement du virus de l'hepatite b et de flavivirus par l'helioxanthine et ses analogues

Country Status (10)

Country Link
US (1) US6306899B1 (fr)
EP (1) EP1107961A4 (fr)
JP (1) JP2002523408A (fr)
CN (1) CN1342156A (fr)
AU (1) AU5578099A (fr)
BR (1) BR9913333A (fr)
CA (1) CA2341540A1 (fr)
MX (1) MXPA01001777A (fr)
TR (1) TR200100642T2 (fr)
WO (1) WO2000010991A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150967A1 (fr) * 1998-10-20 2001-11-07 Shea Farn Yeh Composes et methodes therapeutiques
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7537764B2 (en) 2004-12-20 2009-05-26 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7735636B2 (en) 2004-06-01 2010-06-15 Flexlink Components Ab Arrangement and method for adjustment of rail at a conveyor
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
TWI399214B (zh) * 2011-05-04 2013-06-21 Univ China Medical 製備奈米多醣體複合粒子之方法及其用途
CN104804014A (zh) * 2015-03-27 2015-07-29 云南民族大学 一种Icetexane型二萜二聚体类化合物及其制备方法和应用
CN114989131A (zh) * 2022-05-30 2022-09-02 云南大学 N’-(2-(苯并[1,3]二氧戊烷-5-基)酰基)芳酰肼类化合物及其合成和用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
US20030215917A1 (en) * 2002-04-04 2003-11-20 Mingjun Huang Assay for evaluation of activity of compounds against HCV using a novel detection system in the HCV replicon
MXPA04009986A (es) * 2002-04-12 2005-08-16 Achillion Pharmaceuticals Inc Metodo para sintetizar beta-l-5-fluoro-2¦,3¦-didesoxi-2¦,3¦-dideshidrocitidina (¦-l-fd4c).
TWI293248B (en) * 2002-05-23 2008-02-11 Nat Health Research Institutes Anti-virus compounds
WO2006136601A1 (fr) * 2005-06-23 2006-12-28 Crucell Holland B.V. Optimisation d’anticorps anti virus nil ouest
CN103351435B (zh) * 2006-06-06 2015-08-19 克鲁塞尔荷兰公司 具有杀灭葡萄球菌活性的人结合分子及其应用
US20100068147A1 (en) * 2006-10-05 2010-03-18 Agency for Science , Technology and Research Dengue diagnosis and treatment
JP6041877B2 (ja) * 2011-08-12 2016-12-14 サザン リサーチ インスティテュート キナゾリノン類似体及び特定のウイルス感染症の治療又は予防へのキナゾリノン類似体の使用
CN103381162A (zh) * 2013-07-04 2013-11-06 丁圣雨 Chukrasone A在治疗登革病毒感染药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486445A (en) * 1983-01-12 1984-12-04 E. I. Du Pont De Nemours And Company Justicidin insecticidal and antiviral compounds
JPS61215394A (ja) * 1985-03-19 1986-09-25 Taisho Pharmaceut Co Ltd ナフタレン型リグナンラクトンン中間体の製造方法
US5070103A (en) * 1985-01-10 1991-12-03 Tanabe Seiyaku Co., Ltd. Naphthalene derivatives and composition and methods of use, and aldehyde intermediates
WO1995001950A1 (fr) * 1993-07-06 1995-01-19 Tsumura & Co. Derive de tetrahydronaphtalene, son procede de production et remede contre une infection a retrovirus le contenant comme ingredient actif
US5834507A (en) * 1994-11-14 1998-11-10 Universidad De Salamanca Antineoplastic cyclolignan derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673575A (en) 1985-04-26 1987-06-16 Fox Chase Cancer Center Composition, pharmaceutical preparation and method for treating viral hepatitus
US4937074A (en) 1988-03-29 1990-06-26 Fox Chase Cancer Center Method of treating retrovirus infection
US5015739A (en) 1988-04-22 1991-05-14 Schering Corporation Processes for preparation of cyclopentyl purine derivatives
US5817638A (en) 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US4999428A (en) 1989-04-14 1991-03-12 Schering Corporation Process for preparing cyclopentyl purine derivatives
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5595739A (en) 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
JP3769737B2 (ja) 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
WO1996025929A1 (fr) * 1995-02-21 1996-08-29 Takeda Chemical Industries, Ltd. Utilisation de l'helioxanthine comme activateur de facteurs induisant la differenciation cellulaire
JPH09227568A (ja) * 1996-02-28 1997-09-02 Takeda Chem Ind Ltd ヘリオキサンチンの製造法
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5821242A (en) 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
WO1998007437A1 (fr) 1996-08-16 1998-02-26 Hepaguard Co., Ltd. COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE L'HEPATITE B A BASE D'EXTRAIT DE Phyllanthus ussuriensis ET/OU DE $i(Phyllanthus urinaria)
ID18046A (id) * 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd Senyawa siklik campuran, pembuatan dan penngunaannya.
CA2285402A1 (fr) * 1997-04-25 1998-11-05 Kohei Notoya Derives amides, leur production et leur utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486445A (en) * 1983-01-12 1984-12-04 E. I. Du Pont De Nemours And Company Justicidin insecticidal and antiviral compounds
US5070103A (en) * 1985-01-10 1991-12-03 Tanabe Seiyaku Co., Ltd. Naphthalene derivatives and composition and methods of use, and aldehyde intermediates
JPS61215394A (ja) * 1985-03-19 1986-09-25 Taisho Pharmaceut Co Ltd ナフタレン型リグナンラクトンン中間体の製造方法
WO1995001950A1 (fr) * 1993-07-06 1995-01-19 Tsumura & Co. Derive de tetrahydronaphtalene, son procede de production et remede contre une infection a retrovirus le contenant comme ingredient actif
US5834507A (en) * 1994-11-14 1998-11-10 Universidad De Salamanca Antineoplastic cyclolignan derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEM. PHARM. BULL.,, vol. 26, no. 10, 1978, pages 3195 - 3198 *
CHEMICAL ABSTRACTS, vol. 123, no. 17, 23 October 1995, Columbus, Ohio, US; abstract no. 227979H, TANAKA M. ET AL.: "Preparation of tetrahydronaphthalene derivative and retrovirus infection remedy containing the same as active ingredient" page 1169; XP002924736 *
CHEMICAL ABSTRACTS, vol. 90, no. 13, 26 March 1979, Columbus, Ohio, US; abstract no. 103877D, MOMOSE T. ET AL.: "Synthetic studies on lignans and related compounds VIII. Synthesis of justicidin B and diphylin and of taiwanin C and E from 2,3-dibenzylidenebutyrolactones via beta-apolignans: a chemical model for natural co-occurrence of 4-hydrogen- and 4-hydroxy-1-phenyl-2,3-napthalides in plants" page 587; XP002924737 *
See also references of EP1107961A4 *
SWOBODA G.A.: "Phytochemical Studies. Part V. The Synthesis of Taiwanese A", J. CHEM. SOC. (C),, 1967, pages 161 - 162, XP002924735 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1150967A1 (fr) * 1998-10-20 2001-11-07 Shea Farn Yeh Composes et methodes therapeutiques
EP1150967A4 (fr) * 1998-10-20 2003-03-05 Shea Farn Yeh Composes et methodes therapeutiques
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
US7754718B2 (en) 2004-05-05 2010-07-13 Yale University Antiviral helioxanthin analogs
US7735636B2 (en) 2004-06-01 2010-06-15 Flexlink Components Ab Arrangement and method for adjustment of rail at a conveyor
US7537764B2 (en) 2004-12-20 2009-05-26 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US8911738B2 (en) 2005-05-12 2014-12-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
TWI399214B (zh) * 2011-05-04 2013-06-21 Univ China Medical 製備奈米多醣體複合粒子之方法及其用途
CN104804014A (zh) * 2015-03-27 2015-07-29 云南民族大学 一种Icetexane型二萜二聚体类化合物及其制备方法和应用
CN114989131A (zh) * 2022-05-30 2022-09-02 云南大学 N’-(2-(苯并[1,3]二氧戊烷-5-基)酰基)芳酰肼类化合物及其合成和用途

Also Published As

Publication number Publication date
TR200100642T2 (tr) 2001-07-23
BR9913333A (pt) 2001-05-15
US6306899B1 (en) 2001-10-23
AU5578099A (en) 2000-03-14
EP1107961A1 (fr) 2001-06-20
EP1107961A4 (fr) 2002-01-30
CN1342156A (zh) 2002-03-27
CA2341540A1 (fr) 2000-03-02
MXPA01001777A (es) 2002-06-04
JP2002523408A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
US6306899B1 (en) Inhibition and treatment of Hepatitis B virus and Flavivirus by Helioxanthin and its analogs
WO2020030143A1 (fr) Composé de cétoamide et procédé de préparation, composition pharmaceutique et utilisation associée
CN101247807A (zh) 噻唑化合物及使用方法
US20110098261A1 (en) Triterpenoid-based compounds useful as virus inhibitors
US6911460B2 (en) Antiviral agents and methods of treating viral infections
US20110212986A1 (en) Anti-flavivirus therapeutic
US7754718B2 (en) Antiviral helioxanthin analogs
JPH02196720A (ja) 脳疾患用剤
WO2009154248A1 (fr) Composition pharmaceutique pour le traitement ou la prévention d'une infection par le virus de l'hépatite b (vhb)
CA2102120A1 (fr) Utilisation d'un derive 1,3-oxathlolane pour le traitement de l'hepatite b
CN101966176B (zh) 含笑内酯及其衍生物用于治疗丙型肝炎的用途
CN105777829B (zh) 一种含有类核苷结构的前药、其制备方法、药物组合物及其用途
EP2088152B1 (fr) Acide n'-{n-[3-oxo-lupan-28-oil]-9-aminononanoil}-3-amino-3-phénylpropionique et ses sels pharmaceutiquement acceptables, procédé de fabrication et son utilisation en tant que médicament
CN102558126B (zh) 2-取代色原酮类化合物及其制备方法和用途
JP2007530600A (ja) 抗ウイルス剤
US5760065A (en) Anti-HIV agent
JPH07242543A (ja) 肝疾患治療剤
JPH11209282A (ja) ベルゲニン及びその誘導体を有効成分とする肝機能改善剤
CN114456190B (zh) 卡山烷二萜phanginin A衍生物及其药物组合物和其应用
WO2022225035A1 (fr) Dérivé d'acide biliaire ayant un effet antiviral sur le virus de l'hépatite b
CN107522716A (zh) 丙型肝炎病毒抑制剂及应用
GB2074165A (en) Nonaprenylamine derivatives
EP0350260B1 (fr) Composés de l'acide oxamique et composition pharmaceutique pour utilisation dans l'amélioration de fonctions cérébrales lésées
JPH07242655A (ja) １，４−ベンゾジオキサン誘導体
CN114796204A (zh) 安莎三烯类化合物在抗病毒感染药物中的用途及制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99810104.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001777

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017002237

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2341540

Country of ref document: CA

Ref document number: 2341540

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/00642

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1999942389

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 55780/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999942389

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1020017002237

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017002237

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999942389

Country of ref document: EP